37008results about "Metabolism disorder" patented technology

Embodiments of the present disclosure provide insulin formulations having a near neutral pH and improved pharmacokinetic / pharmacodynamic properties, and uses in insulin infusion devices that may provide extended infusion period up to 7-14 days. Also provided are systems for administering insulin, the system may include a first reservoir, a second reservoir, an insulin pump configured to administer contents of the first reservoir or the second reservoir, and one or more hardware processors in communication with the insulin pump.

Disclosed in the present invention are a GLP-1 receptor agonist, and a preparation method therefor and a use thereof. Specifically, disclosed are a compound represented by formula (I), and a use thereof in preparation of a drug for treating or preventing GLP-1 receptor-mediated diseases.

A benzo nitrogen-containing heterocyclic derivative regulator, a preparation method therefor and a use thereof. Particularly, the present invention relates to a compound represented by general formula (XIX), a preparation method therefor, a pharmaceutical composition containing the compound, and a use of the compound as a regulator in the preparation of drugs for treating metabolic diseases and related diseases, wherein each substituent in the general formula (XIX) is the same as the definition in the description.

Provided herein are compounds of Formula I" and Formula II and compositions thereof that are capable of disrupting, interrupting, and / or preventing an interaction between a small GTPase protein and a PI3K protein (e.g., PI3Ka). The present disclosure also provides methods of treating cancers and other indications with such compounds or compositions thereof.

Provided herein are compounds of Formula (I) and Formula (II) and compositions thereof that capable of disrupting, interrupting, and / or preventing an interaction between a small GTPase protein and a PI3K protein (e.g., PI3Kα). The present disclosure also provides methods of treating cancers and other indications with such compounds or compositions thereof. (I) (II)

The invention provides a polypeptide or a derivative and a pharmaceutically acceptable salt thereof. The amino acid sequence of the polypeptide is as shown in SEQ ID NO: 1. The polypeptide or the derivative and the pharmaceutically acceptable salt thereof disclosed by the invention can be combined with GLP-1R and GCGR, and is used for effectively activating the GLP-1R and the GCGR. Therefore, the polypeptide or the derivative and the pharmaceutically acceptable salt thereof can be used for detecting GLP-1R and / or GCGR, and can also be used for treating or preventing GLP-1R and / or GCGR related diseases (such as metabolic disorder related diseases, such as obesity, diabetes, fatty liver diseases, non-alcoholic fatty liver diseases and the like).

The present invention relates to a nitrogen-containing heterocyclic derivative inhibitor, and a preparation method therefor and the use thereof. In particular, the present invention relates to a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof as an inhibitor in the treatment of diseases such as cardiovascular diseases and cerebrovascular diseases, wherein the definition of each substituent in general formula (I) is the same as that defined in the description.

The invention relates to an inhibitor containing cyclopentane derivatives as well as a preparation method and application of the inhibitor. Particularly, the invention relates to a compound shown in a general formula (I), a preparation method of the compound, a pharmaceutical composition containing the compound and application of the compound as an inhibitor in treatment of cardiovascular diseases, cerebrovascular diseases and other diseases, and substituents in the general formula (I) are as defined in the specification. # imgabs0 #

The present invention is in the field of pharmaceutical chemistry, and relates to a compound containing a multi-fused ring structure, specifically to a compound of formula (I), a stereoisomer or pharmaceutically acceptable salt thereof, a preparation method therefor, or a pharmaceutical composition thereof, and a use thereof in the preparation of a drug for treating diabetes or obesity-related diseases.

The invention discloses a method for preparing diglyceride with the effects of reducing blood fat, total cholesterol, blood sugar and uric acid through enzymolysis and a product and application of the diglyceride, and belongs to the technical field of diglyceride production.The method comprises the following steps that 1, vegetable oil, glycerin, compound lipase and water are mixed to be subjected to a glycerolysis reaction, and a reactant is obtained; (2) separating reactants, and collecting supernatant; (3) performing distillation separation on the supernatant, and performing decoloration and deodorization to obtain diglyceride; the vegetable oil in the step (1) is low-erucic acid rapeseed oil and corn oil; the composite lipase in the step (1) is prepared from mucor javanicus lipase, aspergillus niger lipase and aspergillus oryzae lipase in a mass ratio of (2-4): 1: (5-8). According to the invention, the use amount of enzyme can be reduced, the cost is reduced, and the prepared diglyceride has better activity of reducing blood fat, total cholesterol, blood sugar and uric acid, and has more advantages in the preparation of health care products.

The invention relates to a phenyl-containing heterocyclic derivative regulator as well as a preparation method and application thereof. In particular, the present invention relates to a compound represented by general formula (XVI), a preparation method thereof, a pharmaceutical composition containing the compound, and an application of the compound as a regulator in the preparation of drugs for treating metabolic diseases and related diseases, each substituent in the general formula (XVI) being as defined in the specification # imgabs0 #

The invention provides a tetrahydropyridinopyrazole derivative and application thereof in medicine, and particularly relates to a compound shown in a general formula (I) or a stereoisomer, a tautomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or eutectic of the compound, and an intermediate and a preparation method of the tetrahydropyridinopyrazole derivative. The invention also relates to application in preparation of related medicines for treating diabetes mellitus. # imgabs0 #

To provide constructs, vectors, relative host cells and pharmaceutical compositions which allow an effective gene therapy, in particular of genes larger than 5Kb.SOLUTION: The present invention implements cellular large protein reconstitution by providing to a target cell two or more fragments of large protein fused to split inteins to promote intein-mediated trans-splicing and reconstitute the functional protein.SELECTED DRAWING: None

Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.

The present application discloses compounds of formula I for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The present invention particularly relates to a Lactiplantibacillus plantarum strain having a weight-reducing function, a live bacterium formulation, a preparation method therefor, and the use thereof. The Lactiplantibacillus plantarum strain is preserved in China General Microbiological Culture Collection Center (CGMCC) of China Committee for Culture Collection of Microorganisms, the accession number thereof being CGMCC No. 25683. The Lactiplantibacillus plantarum strain and the live bacterium formulation thereof can inhibit the growth of an obesity bacterial strain Enterobacter cloacae, reduce the cholesterol, and inhibit the differentiation of 3T3-L1 preadipocytes, so as to reduce the body weight of an obesity model mouse and reduce the total weight gain and total food utilization rate of an obesity model rat, thereby achieving an excellent weight-reducing function.

A nitrogen-containing fused ring compound as a GLP-1 receptor agonist, and a preparation method therefor and the use thereof. Specifically, provided are a compound as represented by formula (I), and the use thereof in the preparation of a drug for treating or preventing diseases mediated by GLP-1.

The invention discloses a nitrogen-containing bridged ring compound serving as a GLP-1 receptor agonist as well as a preparation method and application of the nitrogen-containing bridged ring compound. Specifically, the invention discloses a compound as shown in a formula (I), and application of the compound in preparation of drugs for treating or preventing GLP-1 mediated diseases. # imgabs0 #

The present invention provides a pharmaceutical composition for treating IL-6-related diseases containing an IL-6 inhibitor as an active ingredient, wherein the pharmaceutical composition is routinely administered after a short-interval dosing period where the same dose as the routine dose is administered at a shorter interval than the routine dosing interval.

Disclosed herein are “ketone body-HMB” or “KB-HMB” compositions including a combination of: (1) hydroxymethyl butyrate; (2) a ketone body component such as beta-hydroxybutyrate (BHB) and / or acetoacetate; and (3) optionally a dietetically or pharmaceutically acceptable carrier. Also disclosed herein are methods of using such compositions for producing desired physiological effects, such as fat loss, in a mammal. The compositions beneficially enhance fat loss through ketosis while also reducing or eliminating muscle wasting and / or promoting muscle formation.

A long-acting injection preparation and a preparation method therefor. The preparation contains an active compound such as the compound as shown in formula (I) or formula (II), or compound 6, or a stereoisomer, pharmaceutically acceptable salt or deuterated compound thereof, and at least one pharmaceutically acceptable carrier.

The present invention provides a compound as shown in formula (I), and a pharmaceutically acceptable salt of the compound. The compound in the present invention exhibits a strong inhibitory effect on Lp(a) assembly, and can be used for treating cardiovascular diseases (CVD).

The present disclosure provides new prime editor guide RNAs for prime editing, constructs for prime editing, and methods for using same. In addition, the present disclosure provides compositions and methods for conducting prime editing of a target DNA molecule (e.g., a genome) that enables the incorporation of a nucleotide change and / or targeted mutagenesis (e.g., insertion or deletion). The nucleotide change can include a single-nucleotide change (e.g., any transition or any transversion), an insertion of one or more nucleotides, or a deletion of one or more nucleotides. More in particular, the disclosure provides fusion proteins comprising nucleic acid programmable DNA binding proteins (napDNAbp) and a polymerase (e.g., reverse transcriptase), which is guided to a specific DNA sequence by a prime editor RNA (PEgRNA). The prime editor guide RNA comprises an extension arm that provides a DNA synthesis template sequence which encodes a single strand DNA flap, which is homologous to an endogenous DNA sequence, but which contains the desired one or more nucleotide changes and which, following synthesis by the polymerase (e.g., reverse transcriptase), becomes incorporated into the target DNA molecule.

The invention aims to provide a crystal form of a thyroid hormone receptor agonist, a preparation method, a pharmaceutical composition and application of the crystal form in preparation of a TRbeta selective agonist medicine. Compared with the prior art, the crystal form provided by the invention has one or more improved properties, and is of great significance to further development of the medicine.

The present disclosure relates generally to GLP-1 agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.